These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Parikh UM; Mellors JW Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640 [TBL] [Abstract][Full Text] [Related]
3. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746 [TBL] [Abstract][Full Text] [Related]
4. Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project. Tang EC; Vittinghoff E; Anderson PL; Cohen SE; Doblecki-Lewis S; Bacon O; Coleman ME; Buchbinder SP; Chege W; Kolber MA; Elion R; Shlipak M; Liu AY J Acquir Immune Defic Syndr; 2018 Feb; 77(2):193-198. PubMed ID: 28991887 [TBL] [Abstract][Full Text] [Related]
5. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement. ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747 [TBL] [Abstract][Full Text] [Related]
6. HIV Preexposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate Among Cisgender Women. Marrazzo J; Tao L; Becker M; Leech AA; Taylor AW; Ussery F; Kiragu M; Reza-Paul S; Myers J; Bekker LG; Yang J; Carter C; de Boer M; Das M; Baeten JM; Celum C JAMA; 2024 Mar; 331(11):930-937. PubMed ID: 38427359 [TBL] [Abstract][Full Text] [Related]
7. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602 [TBL] [Abstract][Full Text] [Related]
8. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges. Krakower DS; Mayer KH Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022 [TBL] [Abstract][Full Text] [Related]
9. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Okwundu CI; Uthman OA; Okoromah CA Cochrane Database Syst Rev; 2012 Jul; 2012(7):CD007189. PubMed ID: 22786505 [TBL] [Abstract][Full Text] [Related]
10. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States. Adams JL; Shelley K; Nicol MR Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960 [TBL] [Abstract][Full Text] [Related]
11. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD; Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772 [TBL] [Abstract][Full Text] [Related]
12. Emtricitabine/tenofovir disoproxil fumarate: a review of its use in HIV-1 pre-exposure prophylaxis. Plosker GL Drugs; 2013 Mar; 73(3):279-91. PubMed ID: 23444256 [TBL] [Abstract][Full Text] [Related]
13. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial. Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709 [TBL] [Abstract][Full Text] [Related]
14. Preexposure Prophylaxis for the Prevention of HIV: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. Chou R; Spencer H; Bougatsos C; Blazina I; Ahmed A; Selph S JAMA; 2023 Aug; 330(8):746-763. PubMed ID: 37606667 [TBL] [Abstract][Full Text] [Related]
15. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128 [TBL] [Abstract][Full Text] [Related]
16. Why Are Patients Switching from Tenofovir Disoproxil Fumarate/Emtricitabine (Truvada) to Tenofovir Alafenamide/Emtricitabine (Descovy) for Pre-Exposure Prophylaxis? D'Angelo AB; Westmoreland DA; Carneiro PB; Johnson J; Grov C AIDS Patient Care STDS; 2021 Aug; 35(8):327-334. PubMed ID: 34375141 [TBL] [Abstract][Full Text] [Related]
17. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention. Mugwanya KK; Baeten JM Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852 [TBL] [Abstract][Full Text] [Related]
18. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. Molina JM; Capitant C; Spire B; Pialoux G; Cotte L; Charreau I; Tremblay C; Le Gall JM; Cua E; Pasquet A; Raffi F; Pintado C; Chidiac C; Chas J; Charbonneau P; Delaugerre C; Suzan-Monti M; Loze B; Fonsart J; Peytavin G; Cheret A; Timsit J; Girard G; Lorente N; Préau M; Rooney JF; Wainberg MA; Thompson D; Rozenbaum W; Doré V; Marchand L; Simon MC; Etien N; Aboulker JP; Meyer L; Delfraissy JF; N Engl J Med; 2015 Dec; 373(23):2237-46. PubMed ID: 26624850 [TBL] [Abstract][Full Text] [Related]
19. Kidney function and daily emtricitabine/tenofovir disoproxil fumarate pre-exposure prophylaxis against HIV: results from the real-life multicentric demonstrative project PrEP Brazil. Petruccelli KCS; Baía-da-Silva DC; Val F; Valões MS; Cubas-Vega N; Silva-Neto AV; Sampaio V; Alencar A; Pecoits-Filho R; Moreira RC; Cardoso SW; Moreira RI; Leite IC; Madruga JV; Kallas EG; Alencastro PR; Hoagland B; Grinsztejn B; Santos VGV; Lacerda MVG AIDS Res Ther; 2022 Feb; 19(1):12. PubMed ID: 35209929 [TBL] [Abstract][Full Text] [Related]
20. Systemic preexposure prophylaxis for HIV: translating clinical data to clinical practice. Li J; Dufrene SL; Okulicz JF Ann Pharmacother; 2014 Apr; 48(4):507-18. PubMed ID: 24473492 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]